Company Filing History:
Years Active: 2025
Title: David Verne Hansen: Innovator in Neuroprotective Antibodies
Introduction
David Verne Hansen is a notable inventor based in Mapleton, UT (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target human TREM2. His work has implications for neuroprotection and the treatment of neurodegenerative diseases.
Latest Patents
David Verne Hansen holds a patent for "Agonists of TREM2." This application discloses certain antibodies that specifically bind to human TREM2, a receptor expressed on myeloid cells. The antibodies act as TREM2 agonists and are designed to bind to the stalk region of intact human TREM2 without interacting with soluble TREM2. The patent outlines various embodiments where these antibodies demonstrate high specificity and affinity, with dissociation constants ranging from 10 nM to as low as 1-10 pM. Additionally, the antibodies inhibit the shedding of soluble TREM2 and enhance the survival of human microglia cells, potentially providing neuroprotective activities.
Career Highlights
David Verne Hansen is associated with Genentech, Inc., a leading biotechnology company known for its innovative research and development in pharmaceuticals. His work at Genentech has allowed him to focus on groundbreaking research that aims to improve the understanding and treatment of neurological conditions.
Collaborations
David has collaborated with notable colleagues, including Ainhoa Echeverria Larraza and Isidro Hotzel. These collaborations have contributed to the advancement of research in the field of neurobiology and antibody development.
Conclusion
David Verne Hansen's innovative work in developing TREM2 agonists showcases his commitment to advancing biotechnology and improving neuroprotective strategies. His contributions are significant in the ongoing efforts to combat neurodegenerative diseases.